Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats.

[1]  W. Gomaa,et al.  Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. , 2009, Pharmacological research.

[2]  Hai Xu,et al.  Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. , 2009, Toxicology letters.

[3]  M. Štěrba,et al.  Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron , 2009, Pharmacological reports : PR.

[4]  Rebecca S. Moore,et al.  NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  M. Kalmanti,et al.  Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity , 2008, Pediatric blood & cancer.

[6]  Narine Sarvazyan,et al.  Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. El-Shitany,et al.  Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  C. Napoli,et al.  Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. , 2008, European journal of cancer.

[9]  S. Yusuf,et al.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation , 2007, International journal of nanomedicine.

[10]  R. Schulz,et al.  Pimecrolimus: a review , 2022 .

[11]  H. Kawachi,et al.  Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1 , 2007, Hypertension.

[12]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[13]  G. Bakris,et al.  Beta blockers in the management of chronic kidney disease. , 2006, Kidney international.

[14]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[15]  P. Veeraveedu,et al.  Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. , 2006, International journal of cardiology.

[16]  H. Schultheiss,et al.  Myocardial proteases and matrix remodeling in inflammatory heart disease. , 2006, Cardiovascular research.

[17]  Anne M Deschamps,et al.  Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. , 2006, Cardiovascular research.

[18]  A. Atessahin,et al.  Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. , 2006, Toxicology.

[19]  G. Takemura,et al.  Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy , 2006, Circulation.

[20]  E. Thiel,et al.  Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma , 2005, Cancer.

[21]  Z. Miloradović,et al.  Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. , 2005, Clinical nephrology.

[22]  T. Kyo,et al.  Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. , 2004, Internal medicine.

[23]  A. Ballestrero,et al.  Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. , 2004, Journal of molecular and cellular cardiology.

[24]  R. Touyz.  Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? , 2004, Hypertension.

[25]  Anthony J. Muslin,et al.  Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. , 2004, Biochemical and biophysical research communications.

[26]  G. Christensen,et al.  Elevated Levels of Activin A in Heart Failure: Potential Role in Myocardial Remodeling , 2004, Circulation.

[27]  C. Szabó,et al.  Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. , 2004, Oncology reports.

[28]  H. Hrstkova,et al.  The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer , 2003, European Journal of Pediatrics.

[29]  J. Groves,et al.  Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction , 2003, Circulation.

[30]  Kenichi Watanabe,et al.  Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy , 2000, British journal of pharmacology.

[31]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[32]  D. Sawyer,et al.  Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. , 1999, Circulation research.

[33]  G. Feuerstein,et al.  Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. , 1996, European heart journal.

[34]  L. Kedes,et al.  Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Hochstein,et al.  Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. , 1977, Biochemical and biophysical research communications.

[36]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[37]  L. B. Foster,et al.  A single-reagent manual method for directly determining urea nitrogen in serum. , 1971, Clinical chemistry.

[38]  H. Husdan,et al.  Estimation of creatinine by the Jaffe reaction. A comparison of three methods. , 1968, Clinical chemistry.

[39]  Ying Zhu,et al.  [Relationship between glomerular nephrin expression and oxidative stress reaction in rats with adriamycin-induced nephrosis]. , 2009, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics.

[40]  E. Bárdi,et al.  Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer , 2008, Pathology & Oncology Research.

[41]  Sudhir V. Shah,et al.  Oxidants in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[42]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[43]  R. Calabro',et al.  Anthracycline-Induced Cardiotoxicity in Children with Cancer , 2005, Paediatric drugs.

[44]  R. Danesi,et al.  Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs , 2002, Clinical pharmacokinetics.